Cilostazol is a quinolone derivative and is FDA approved for the treatment of intermittent claudication associated with early-stage peripheral vascular disease.

Cilostazol has also been used off-labeled for the long-term prevention of severe vascular events in patients with a history of transient ischemic attack or non-cardioembolic ischemic stroke.